{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:32:55Z","timestamp":1786649575105,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Tuberculosis (TB) is caused by\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      . Treatment regimen with the first-line anti-tubercular drug remains the foundation of treatment for drug-sensitive TB. The fixed-dose combination of drugs regime is associated with adverse drug reactions (ADRs) such as drug-induced liver injury (DILI), myalgia, arthralgia, hearing loss, gastrointestinal disturbances, visual disturbances, central nervous disorders and hypersensitivity reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>This study aimed to analyse the spectrum and severity of ADRs with emphasis on DILI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study was conducted from 2015 to 2023 at a tertiary care teaching hospital. A total of 108 patients were included in the study. The spectrum of ADRs was classified as per the World Health Organization systems organ classes. The seriousness of the reaction was classified as serious and non-serious. The severity of DILI was categorized into five grades.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 126 ADRs were reported. DILI was the most reported ADR followed by vomiting and itching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study seeks to enhance the clinicians\u2019 understanding of the diverse ADRs linked to anti-TB treatment, encouraging them to provide better patient counselling, prioritise safety and actively report even mild ADRs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/npmj.npmj_186_25","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:00:23Z","timestamp":1767337223000},"page":"25-28","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Adverse Drug Reaction to First-Line Oral Antitubercular Drugs: An 8-Year Analysis from a Tertiary Centre in Eastern India"],"prefix":"10.4103","volume":"33","author":[{"given":"Ratikanta","family":"Tripathy","sequence":"first","affiliation":[{"name":"Deparment of Pharmacology, KIMS, KIIT, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Singh","sequence":"additional","affiliation":[{"name":"Deparment of Pulmonary Medicine, KIMS, KIIT, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasis","family":"Behera","sequence":"additional","affiliation":[{"name":"Deparment of Pulmonary Medicine, KIMS, KIIT, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Paikray","sequence":"additional","affiliation":[{"name":"Deparment of Pharmacology, KIMS, KIIT, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saswat","family":"Subhankar","sequence":"additional","affiliation":[{"name":"Deparment of Pulmonary Medicine, KIMS, KIIT, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangala Charana","family":"Das","sequence":"additional","affiliation":[{"name":"Deparment of Pharmacology, KIMS, KIIT, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"R1-20260420","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1021\/acs.jmedchem.2c00227","article-title":"Tuberculosis drug discovery: Challenges and new horizons","volume":"65","author":"Fernandes","year":"2022","journal-title":"J Med Chem"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cid\/ciab908","article-title":"Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: A prospective population pharmacokinetic study","volume":"75","author":"Denti","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R5-20260420","first-page":"144","article-title":"Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years","volume":"21","author":"Castro","year":"2015","journal-title":"Rev Port Pneumol (2006)"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"e19566","DOI":"10.1371\/journal.pone.0019566","article-title":"Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: A prospective cohort study","volume":"6","author":"Lorent","year":"2011","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"R7-20260420","first-page":"S8","article-title":"Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis","volume":"3","author":"Singh","year":"2015","journal-title":"Clin Epidemiol Glob Health"},{"key":"R8-20260420","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/ajhp\/52.4.417","article-title":"ASHP guidelines on adverse drug reaction monitoring and reporting","volume":"52","year":"1995","journal-title":"Am J Health Syst Pharm"},{"key":"R10-20260420","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1164\/ajrccm.164.7.2109052","article-title":"Hepatotoxicity from rifampin plus pyrazinamide: Lessons for policymakers and messages for care providers","volume":"164","author":"Burman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/pds.4155","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden","volume":"26","author":"Holm","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","article-title":"CSH guidelines for the diagnosis and treatment of drug-induced liver injury","volume":"11","author":"Yu","year":"2017","journal-title":"Hepatol Int"},{"key":"R14-20260420","first-page":"584","article-title":"A study on assessment of adverse drug reactions in tuberculosis","volume":"2","author":"Ramanath","year":"2012","journal-title":"Am J Pharm Tech Res"},{"key":"R15-20260420","first-page":"99","article-title":"A study on assessment of adverse drug reactions in patients with tuberculosis in a tertiary care teaching hospital","volume":"8","author":"Shareef","year":"2018","journal-title":"J Appl Pharm Sci"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4103\/picr.PICR_279_20","article-title":"Adverse drug reaction profile of daily regimen antituberculosis treatment","volume":"13","author":"Sankar","year":"2022","journal-title":"Perspect Clin Res"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1164\/rccm.2108091","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment","volume":"166","author":"Sharma","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1440-1746.2012.07279.x","article-title":"Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury","volume":"28","author":"Devarbhavi","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1111\/jcmm.15474","article-title":"Hinokiflavone induces apoptosis via activating mitochondrial ROS\/JNK\/caspase pathway and inhibiting NF-\u03baB activity in hepatocellular carcinoma","volume":"24","author":"Mu","year":"2020","journal-title":"J Cell Mol Med"},{"key":"R20-20260420","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1007\/s11033-021-06674-6","article-title":"Mitochondrial stress response in drug-induced liver injury","volume":"48","author":"Zheng","year":"2021","journal-title":"Mol Biol Rep"},{"issue":"Suppl 1","key":"R21-20260420","first-page":"S131","article-title":"Potential disadvantages associated with treatment of active tuberculosis using fixed-dose combination: A review of literature","volume":"8","author":"Iftikhar","year":"2017","journal-title":"J Basic Clin Pharm"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1002\/hep.23534","article-title":"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome","volume":"51","author":"Kumar","year":"2010","journal-title":"Hepatology"},{"key":"R23-20260420","first-page":"531","article-title":"Study of adverse drug reactions caused by first line anti-tubercular drugs used in directly observed treatment, short course (DOTS) therapy in Western Nepal, Pokhara","volume":"58","author":"Chhetri","year":"2008","journal-title":"J Pak Med Assoc"},{"key":"R24-20260420","first-page":"941","article-title":"Severe arthropathy with ofloxacin in two cases of MDR tuberculosis","volume":"2","author":"Arora","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"R25-20260420","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/milmed\/161.11.707","article-title":"Psychotic disorder associated with isoniazid","volume":"161","author":"Bourgeois","year":"1996","journal-title":"Mil Med"},{"key":"R26-20260420","first-page":"e920350","article-title":"Drug-induced liver injury from anti-tuberculosis treatment: A retrospective cohort study","volume":"26","author":"Zhao","year":"2020","journal-title":"Med Sci Monit"}],"container-title":["Nigerian Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_186_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:55:34Z","timestamp":1786647334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/npmj.npmj_186_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/npmj.npmj_186_25","relation":{},"ISSN":["1117-1936","2468-6875"],"issn-type":[{"value":"1117-1936","type":"print"},{"value":"2468-6875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-05-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}